Navigation Links
Daniel B. Dubin, M.D., Joins NanoBio Corp.'s Board of Directors

ANN ARBOR, Mich., July 8 /PRNewswire/ -- NanoBio(R) Corp., a biopharmaceutical company focused on developing and commercializing novel products to prevent and treat infectious diseases, today announced the appointment of Daniel B. Dubin, M.D., to its board of directors.

Dr. Dubin currently serves as Vice Chairman and a Director at Leerink Swann, a leading healthcare and biotechnology investment banking firm.

"Dan's keen understanding of the life sciences investment banking field and his clinical experience as a dermatologist bring a dual perspective that will help us create value and distinction as an emerging company in the biotechnology sector," said James R. Baker Jr., founder and Chairman of NanoBio. "His expertise and informed perspective in the field of dermatology will greatly enhance the strategic positioning of our topical treatments for herpes labialis, onychomycosis and other dermatologic infections."

A Harvard-trained dermatologist, Dr. Dubin served as Ambulatory Medical Director of the dermatology practice at Brigham and Women's Hospital. In 1996, Dr. Dubin co-founded MEDACorp to provide life science companies and institutional investors with expert insight into the development and adoption of biopharmaceuticals, medical devices and diagnostics. When MEDACorp merged with Leerink Swann in 2001, Dr. Dubin became a Director at Leerink Swann and later assumed the position of Vice Chairman. Dr. Dubin also serves on the board of Eleme Medical, a cellulite treatment company.

NanoBio's lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. The company's nanoemulsion-based products have demonstrated potent antimicrobial effects in several phase 1 and 2 clinical trials without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

SOURCE NanoBio Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
2. Anesiva Appoints Daniel Janney to Board of Directors
3. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
4. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
7. OmniSonics Appoints J. Daniel Cole Chairman of the Board
8. PPD Names Daniel Darazsdi as Chief Financial Officer
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
11. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):